Global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders Market

Report ID : 1258 | Published : 2022-06-13 | Pages: | Format: PDF/EXCEL

The Global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders Market is estimated to exhibit a CAGR of 31.4% during the forecast period. 

Cell and gene therapy-based therapies have the potential to be an effective and disease-modifying treatment for diseases that would otherwise be incurable with traditional medicines. Due to the rising demand for cell-based immunotherapies and gene therapy products to treat conditions such as prostate and blood cancers. Another factor driving market expansion is the increasing use of cell therapy products in hospitalized patients to treat burns, venous leg ulcers, diabetic foot ulcers, traumas, and pressure ulcers. Also, due to excellent safety and efficacy profiles for treating a wide range of disorders, specific cell and gene therapy treatments are getting regulatory approvals faster than other medicines. As the approval process becomes more simplified, companies are launching these items on the market more quickly.

Additionally, rising R&D efforts, government initiatives to utilize sustainable components in manufacturing, and investments by major players are likely to generate lucrative revenue opportunities for players in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market over the forecast period. During the projection period, the recurrence of the current pandemic is likely to have a positive impact on the worldwide Gene and Cell Therapies Targeting CNS Disorders market. Due to the increased intervention of life-threatening diseases such as heart disease, AIDS, cystic fibrosis, and age-related problems, the industry is likely to expand its borders. The high cost of gene treatments, on the other hand, is expected to hinder market expansion to some extent throughout the forecast period. 

Market Segmentation:

The Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market is segmented based on product and Indication. Based on the product, the market is segmented as gene therapy and cell therapy. By Indication, the market is segmented into amyotrophic Lateral Sclerosis, Multiple sclerosis, Spinal Cord Injure, Alzheimer, Parkinson Disease, Huntington, and Other Indications. Based on Indications, the Huntington segment is accounted as a major contributor in the Gene and Cell Therapies Targeting CNS Disorders market. The Huntington category is expected to hold a major share in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market in 2021. As a result of the approval of an increasing number of gene therapies for cancer therapy and the segment's growth is being fueled by greater emphasis on research to develop effective cancer treatments, as well as rising cancer research investments.

The market is expected to develop in the coming years due to the availability of numerous gene therapy products that can be used to treat cancer and a huge patient population. Cell therapy segment witness growth at a rapid rate. The cell therapy segment is projected to grow at a rapid rate in the global Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market. The cell therapy segment is growing due to the introduction of innovative and breakthrough products as well as the widespread use of CAR T-cell-based therapies. Cell therapy is the most rapidly developing technology in cancer treatment, with the potential to replace multiple present treatments., especially in countries such as the US, Germany, UK, China, and India.

The North America Gene and Cell Therapies Targeting CNS Disorders market hold a significant revenue share in the region. The North America gene and cell therapy market is expected to show the highest market share in terms of revenue soon. In both regional and global markets, the United States is the major contributor. This is due to the introduction of novel cell and gene therapy products. Due to the elevated prevalence of chronic diseases in countries like China and Japan, APAC is expected to become a key market during the forecast period. Developers of cell and gene therapies are receiving support from both the public and private sectors. In terms of R&D activity and financing to develop and commercialize cell and gene therapy products, North America and Europe are at the forefront. The regulatory approval process, particularly in the United States, is evolving and becoming favourable for vendors for developing cell and gene therapy products.

Competitive Landscape:

The key players in the Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market have shifted their focus towards bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolios and strengthen their market footprint across the globe. Some of the major key players in the Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders market are Novartis, Brainstorm Cell Therapeutics, Helminth, Core set, Q therapeutics, Helminth, Rapa Therapeutics, Brainstorm Cell Therapeutics, Neuroblast, Osteocyte Orchard Therapeutics plc. (UK), SIBIONO (China), Shanghai Sunway Biotech Co., Ltd. (China), bluebird bio, Inc. (US), Human Stem Cells Institute (Russia), Ange’s, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals, Inc. (Ireland), Ackee Therapeutics (US), and Donavan Technologies (US).

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Gene and Cell Therapies Targeting CNS Disorders Market Snapshot

Chapter 4. Global Gene and Cell Therapies Targeting CNS Disorders Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial/Pipeline Analysis

Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Gene Therapy

5.2.2. Cell Therapy

Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis

6.1. By Indications & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

6.2.1. Amyotrophic Lateral Sclerosis

6.2.2. Multiple sclerosis

6.2.3. Spinal Cord Injury

6.2.4. Alzehimer

6.2.5. Parkinson Disease

6.2.6. Huntington

6.2.7. Othe Indications

Chapter 7. Gene and Cell Therapies Targeting CNS Disorders Market Segmentation 4: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Products, 2020-2030

7.1.2. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Indications, 2020-2030

7.1.3. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

7.2. Europe

7.2.1. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2020-2030

7.2.2. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2020-2030

7.2.3. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2020-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2020-2030

7.3.2. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2020-2030

7.3.3. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2020-2030

7.4. Latin America

7.4.1. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2020-2030

7.4.2. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2020-2030

7.4.3. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2020-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2020-2030

7.5.2. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2020-2030

7.5.3. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2020-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Novartis

8.2.2. BrainStorm Cell Therapeutics

8.2.3. Helixmith

8.2.4. Corestem

8.2.5. Q therapeutics

8.2.6. Helixmith

8.2.7. Rapa Therapeutics

8.2.8. BrainStorm Cell Therapeutics

8.2.9. Neuroplast

8.2.10. StemCyte

8.2.11. Ferrer Internacional

8.2.12. Neuralstem

8.2.13. Ferrer Internacional

8.2.14. Stemedica Cell Technologies

8.2.15. Libella Gene Therapeutics

8.2.16. Sangamo Therapeutics

8.2.17. Hoffmann-La Roche

8.2.18. Longeveron

8.2.19. Sio Gene Therapies

8.2.20. Prevail Therapeutics (Eli Lilly and Company)

8.2.21. NeuroGeneration

8.2.22. Brain Neurotherapy Bio (AskBio)

8.2.23. UniQure Biopharma

8.2.24. Neurogene Inc.

8.2.25. Passage Bio

8.2.26. AXOVANT SCIENCES GMBH

8.2.27. MeiraGTx Limited

8.2.28. Asklepios BioPharmaceutical (AskBio)

8.2.29. Biogen

8.2.30. Sarepta Therapeutics

8.2.31. REGENXBIO Inc.

8.2.32. Lysogene

8.2.33. Voyager Therapeutics

8.2.34. PTC Therapeutics

8.2.35. Other Prominent Players

Segmentation of Gene and Cell Therapies Targeting CNS Disorders Targeting CNS Disorders Market-

By Products

  • Gene Therapy
  • Cell Therapy

By Indications

  • Amyotrophic Lateral Sclerosis
  • Multiple sclerosis
  • Spinal Cord Injury
  • Alzheimer
  • Parkinson Disease
  • Huntington
  • Other Indications"

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients